Modulation of GSK-3beta and method of treating proliferative disorders

Details for Australian Patent Application No. 2005262925 (hide)

Owner Agency for Science, Technology and Research

Inventors Yu, Qiang

Agent Wrays

Pub. Number AU-B-2005262925

PCT Pub. Number WO2006/006939

Priority 60/586,296 09.07.04 US

Filing date 8 July 2005

Wipo publication date 19 January 2006

Acceptance publication date 20 January 2011

International Classifications

A61K 33/14 (2006.01) Medicinal preparations containing inorganic active ingredients - Alkali metal chlorides

A61K 31/4015 (2006.01) - having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

A61K 31/404 (2006.01)

A61K 31/506 (1970.01) - not condensed and containing further heterocyclic rings

A61K 31/7105 (2006.01) - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

A61P 31/00 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 35/00 (1970.01) Antineoplastic agents

Event Publications

23 November 2006 PCT application entered the National Phase

  PCT publication WO2006/006939 Priority application(s): WO2006/006939

20 January 2011 Application Accepted

  Published as AU-B-2005262925

19 May 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005262926-A system and method for providing a sample of a product to shoppers

2005262918-Infusion and injection solution of Levodopa